Money

Eli Lilly Stock Tumbles Despite Q1 Earnings Beat: CVS Drops Zepbound from Coverage


Eli Lilly and Company (NYSE: LLY) reported robust first-quarter earnings for 2025, surpassing Wall Street expectations.

However, the pharmaceutical giant’s stock experienced a significant decline, dropping over 7%, following CVS Health’s decision to remove Lilly’s weight-loss drug, Zepbound, from its standard formulary in favor of Novo Nordisk’s Wegovy.

Strong Financial Performance Overshadowed

In Q1 2025, Eli Lilly achieved adjusted earnings per share (EPS) of $3.34, exceeding analyst forecasts of $3.26.

The company’s revenue reached $12.73 billion, up from $6.96 billion in the same quarter the previous year. This growth was primarily driven by strong sales of Mounjaro, a diabetes medication, which generated $3.84 billion, and Zepbound, which brought in $2.31 billion .

Despite these positive results, the company’s stock declined sharply. Investors reacted to the news that CVS Health’s Caremark pharmacy benefit manager would exclude Zepbound from its preferred drug list starting July 1, 2025.

This move favors Novo Nordisk’s Wegovy and Saxenda, potentially limiting patient access to Zepbound and impacting its sales .

CVS’s Strategic Shift

CVS Health’s decision is part of a broader strategy to manage drug costs and improve patient affordability.

By negotiating better pricing with Novo Nordisk, CVS aims to offer Wegovy at a discounted price of approximately $500 per month for uninsured customers. This pricing strategy could make Wegovy more accessible, thereby increasing its market share at the expense of Zepbound .

Market Reaction and Analyst Perspectives

The market responded negatively to these developments. Eli Lilly’s shares fell by more than 7% in early trading, reflecting investor concerns about the potential impact on Zepbound’s market performance and the company’s overall profitability.

Analysts suggest that while the exclusion from CVS’s formulary is a setback, it may prompt Eli Lilly to adjust its pricing strategy and negotiate new deals to maintain competitiveness in the weight-loss drug market .

Looking Ahead

Eli Lilly has reaffirmed its full-year revenue guidance of $58.0 to $61.0 billion but has lowered its adjusted EPS forecast to a range of $20.78 to $22.28, down from the previous estimate of $22.05 to $23.55.

The company attributes this revision to charges related to acquired in-process research and development and external trade uncertainties, including potential tariffs .

Despite the current challenges, Eli Lilly remains the world’s most valuable healthcare company, with a market capitalization exceeding $800 billion.

The company has also announced plans to invest $27 billion in U.S. manufacturing, signaling its commitment to long-term growth and innovation .

Eli Lilly’s strong Q1 financial performance demonstrates the company’s robust product portfolio and market presence.

However, the recent formulary exclusion of Zepbound by CVS Health underscores the competitive and pricing pressures in the pharmaceutical industry.

As the company navigates these challenges, its strategic responses will be crucial in maintaining its market position and achieving its financial goals for the year.

Also Read

theafricalogistics

Recent Posts

McDonald’s and Krispy Kreme Call It Quits: Doughnut Deal Ends Amid Mounting Costs

In a surprise development that’s caught the attention of food lovers and industry watchers alike,…

2 days ago

Nvidia Hits New High: What Its AI-Fueled Rally Signals for the Future of Tech Stocks

Nvidia Corporation (NASDAQ: NVDA) once again made headlines Wednesday as its stock surged to a…

2 days ago

Warehouse Storage Solutions: Optimizing Space with Racking and Mezzanine Systems

In today's fast-paced logistics and manufacturing environments, warehouse space is more valuable than ever. Efficient…

2 days ago

Inside Africa’s Warehouse 4.0: The Rise of Automated Storage Solutions

In recent years, the global logistics landscape has experienced a profound transformation driven by digitization…

3 days ago

Janney Montgomery Scott Sells Over 12,000 Halliburton Shares: What It Means for the Oilfield Services Giant

Investment advisory firm Janney Montgomery Scott LLC has adjusted its position in oilfield services leader…

4 days ago

Why Chery Chose Hybrids Over Full EVs for the South African Market

As the global auto industry accelerates toward full electrification, Chinese automaker Chery is charting a…

4 days ago